Myotonic Dystrophy

Overview

Plain-Language Overview

Myotonic Dystrophy is a genetic disorder that primarily affects the muscles and causes difficulty relaxing them after contraction, known as myotonia. It also impacts other body systems including the heart, eyes, and endocrine glands, leading to a variety of symptoms such as muscle weakness, cataracts, and cardiac arrhythmias. This condition is caused by a mutation in specific genes that disrupt normal muscle function. People with Myotonic Dystrophy often experience progressive muscle wasting and weakness, which can affect daily activities and overall health. The disease can vary in severity and may present at any age, often worsening over time. It is a lifelong condition that requires ongoing medical evaluation.

Clinical Definition

Myotonic Dystrophy is a multisystem autosomal dominant disorder characterized by myotonia, progressive muscle weakness, and systemic involvement including cardiac conduction defects, cataracts, and endocrine abnormalities. It is caused by a trinucleotide repeat expansion mutation in the DMPK gene (type 1) or the CNBP gene (type 2), leading to toxic RNA gain-of-function effects that disrupt normal splicing of multiple transcripts. The hallmark pathology includes myotonia due to impaired muscle relaxation and distal muscle weakness, often accompanied by facial and neck muscle involvement. The disease exhibits anticipation, with earlier onset and increased severity in successive generations. Cardiac complications such as arrhythmias and conduction blocks are major causes of morbidity and mortality. Diagnosis is clinically suspected based on characteristic features and confirmed by genetic testing for the repeat expansions.

Inciting Event

Disease onset is triggered by expansion of CTG repeats during gametogenesis, especially in maternal transmission.
No external environmental or infectious triggers initiate the disease.

Latency Period

Symptoms typically develop in early adulthood but can range from congenital to late-onset forms.
Repeat expansion size influences latency, with larger expansions causing earlier symptom onset.

Diagnostic Delay

Initial symptoms like muscle weakness and myotonia are often attributed to other neuromuscular disorders.
Variable clinical presentation and multisystem involvement can obscure diagnosis.
Lack of awareness of family history or subtle early signs delays genetic testing.

Clinical Presentation

Signs & Symptoms

Progressive distal muscle weakness and wasting with difficulty releasing grip
Myotonia causing stiffness and delayed muscle relaxation
Cataracts developing at a young age
Cardiac conduction defects leading to palpitations or syncope
Endocrine abnormalities such as insulin resistance and testicular atrophy

History of Present Illness

Patients report progressive distal muscle weakness and difficulty releasing grip (myotonia).
Symptoms often begin with facial weakness, ptosis, and difficulty swallowing.
Systemic features include cataracts, cardiac arrhythmias, and endocrine abnormalities developing over time.
Fatigue and daytime sleepiness are common due to central nervous system involvement.

Past Medical History

History of cataract surgery or cardiac conduction abnormalities may be present.
Previous episodes of respiratory insufficiency or aspiration pneumonia can occur due to muscle weakness.
No specific prior infections or exposures are linked to disease progression.

Family History

Positive family history of myotonic dystrophy with autosomal dominant inheritance is common.
Affected relatives often have variable severity and age of onset due to anticipation.
Congenital cases often have mothers with severe myotonic dystrophy and large repeat expansions.

Physical Exam Findings

Facial muscle weakness with a characteristic hatchet face appearance due to muscle atrophy
Myotonia evidenced by delayed muscle relaxation after contraction, especially in the hands
Distal muscle wasting and weakness, particularly in the hands and lower legs
Ptosis and frontal balding are common external features
Cardiac conduction abnormalities may be detected on auscultation or ECG

Diagnostic Workup

Diagnostic Criteria

Diagnosis of myotonic dystrophy is established by identifying characteristic clinical features such as myotonia, distal muscle weakness, and multisystem involvement including cataracts and cardiac conduction abnormalities. Electromyography (EMG) shows myotonic discharges which are pathognomonic. Definitive diagnosis requires genetic testing demonstrating expanded CTG repeats in the DMPK gene for type 1 or CCTG repeats in the CNBP gene for type 2. Family history and clinical examination support the diagnosis but genetic confirmation is essential for definitive diagnosis and counseling. Additional tests such as ECG and ophthalmologic evaluation help assess systemic involvement.

Pathophysiology

Key Mechanisms

CTG trinucleotide repeat expansion in the 3' untranslated region of the DMPK gene causes toxic RNA gain-of-function.
Mutant RNA sequesters muscleblind-like (MBNL) proteins, leading to abnormal alternative splicing of multiple pre-mRNAs.
Aberrant splicing results in defective chloride channel (CLCN1) and insulin receptor isoforms, causing myotonia and insulin resistance.
Progressive muscle fiber atrophy and fibrosis contribute to muscle weakness and wasting.
Cardiac conduction system fibrosis leads to arrhythmias and conduction blocks.

Involvement	Details
Organs	Skeletal muscles are primarily involved causing weakness, myotonia, and muscle wasting.
	Heart involvement causes conduction defects and arrhythmias that can be life-threatening.
	Lens of the eye is affected leading to early-onset cataracts in many patients.
Tissues	Skeletal muscle tissue exhibits fiber atrophy, fibrosis, and myotonia characteristic of the disease.
Tissues	Cardiac conduction tissue is affected leading to arrhythmias and conduction blocks.
Cells	Skeletal muscle fibers are the primary affected cells showing myotonia and progressive weakness in myotonic dystrophy.
Cells	Cardiac myocytes are involved in conduction system abnormalities leading to arrhythmias and heart block.
Chemical Mediators	CTG trinucleotide repeat expansion in the DMPK gene causes toxic RNA accumulation disrupting splicing of multiple transcripts.
Chemical Mediators	ClC-1 chloride channel dysfunction contributes to muscle hyperexcitability and myotonia.

Treatments

Pharmacological Treatments

Mexiletine
- Mechanism:
  - Blocks sodium channels to reduce abnormal muscle membrane excitability causing myotonia.
- Side effects:
  - Gastrointestinal upset
  - Dizziness
  - Cardiac arrhythmias
- Clinical role:
  - First-line
Phenytoin
- Mechanism:
  - Stabilizes neuronal membranes by blocking voltage-gated sodium channels to alleviate myotonia.
- Side effects:
  - Gingival hyperplasia
  - Ataxia
  - Nystagmus
- Clinical role:
  - Second-line
Carbamazepine
- Mechanism:
  - Inhibits voltage-gated sodium channels to reduce muscle hyperexcitability.
- Side effects:
  - Hyponatremia
  - Dizziness
  - Rash
- Clinical role:
  - Second-line

Non-pharmacological Treatments

Regular physical therapy to maintain muscle strength and prevent contractures.
Use of assistive devices such as braces to support weakened muscles and improve mobility.
Cardiac monitoring and pacemaker implantation if conduction abnormalities develop.
Respiratory support including non-invasive ventilation for respiratory muscle weakness.

Prevention

Pharmacological Prevention

Pacemaker implantation to prevent sudden cardiac death from conduction block
Anticholinesterase agents may be used cautiously to improve myotonia
Beta-blockers or antiarrhythmics to manage cardiac arrhythmias
Insulin or oral hypoglycemics for diabetes management
Avoidance of anesthetic agents that exacerbate myotonia during surgery

Non-pharmacological Prevention

Regular cardiac screening with ECG and Holter monitoring
Physical therapy to maintain muscle strength and flexibility
Avoidance of cold exposure to reduce myotonia severity
Swallowing assessments to prevent aspiration
Genetic counseling for affected families

Outcome & Complications

Complications

Sudden cardiac death due to conduction system disease
Respiratory failure from respiratory muscle weakness
Aspiration pneumonia secondary to dysphagia
Infertility related to testicular atrophy
Severe muscle wasting leading to disability

Short-term Sequelae	Long-term Sequelae
Muscle stiffness and cramps exacerbated by cold or stress Transient cardiac arrhythmias causing palpitations or syncope Difficulty swallowing increasing risk of aspiration Daytime fatigue and excessive sleepiness Acute respiratory insufficiency during infections or anesthesia	Progressive muscle weakness leading to wheelchair dependence Chronic cardiac conduction defects requiring pacemaker implantation Permanent respiratory insufficiency necessitating ventilatory support Cataract-induced visual impairment Endocrine dysfunctions including diabetes and hypogonadism

Differential Diagnoses

Myotonic Dystrophy versus Becker Muscular Dystrophy

Myotonic Dystrophy	Becker Muscular Dystrophy
Autosomal dominant inheritance	X-linked recessive inheritance
Adulthood onset	Childhood to adolescence onset
Progressive distal muscle weakness with prominent myotonia	Progressive proximal muscle weakness without myotonia
CTG trinucleotide repeat expansion in the DMPK gene	Reduced or abnormal dystrophin on muscle biopsy or genetic testing

Myotonic Dystrophy versus Facioscapulohumeral Muscular Dystrophy

Myotonic Dystrophy	Facioscapulohumeral Muscular Dystrophy
Autosomal dominant with CTG repeat expansion in DMPK	Autosomal dominant with contraction of D4Z4 repeat on chromosome 4
Distal limb and facial muscle weakness with myotonia	Facial and scapular muscle weakness predominates
Progressive weakness with prominent myotonia	Slowly progressive weakness without myotonia
CTG repeat expansion in DMPK gene	Genetic testing showing D4Z4 repeat contraction

Myotonic Dystrophy versus Hypothyroid Myopathy

Myotonic Dystrophy	Hypothyroid Myopathy
Normal thyroid function tests	Elevated TSH and low free T4
Distal muscle weakness with myotonia	Proximal muscle weakness without myotonia
Chronic progressive course despite thyroid status	Improves with thyroid hormone replacement
CTG repeat expansion in DMPK gene	Thyroid function tests abnormal

Myotonic Dystrophy versus Amyotrophic Lateral Sclerosis (ALS)

Myotonic Dystrophy	Amyotrophic Lateral Sclerosis (ALS)
Distal muscle weakness with myotonia and no upper motor neuron signs	Mixed upper and lower motor neuron signs without myotonia
Slowly progressive weakness with multisystem involvement	Rapidly progressive weakness leading to respiratory failure
EMG showing myotonic discharges	EMG showing widespread denervation and fasciculations

Myotonic Dystrophy versus Pompe Disease (Glycogen Storage Disease Type II)

Myotonic Dystrophy	Pompe Disease (Glycogen Storage Disease Type II)
Adult onset with distal muscle weakness and myotonia	Infantile or childhood onset with cardiomegaly
Normal acid alpha-glucosidase activity	Elevated creatine kinase and acid alpha-glucosidase deficiency
CTG repeat expansion in DMPK gene	Enzyme assay showing deficient acid alpha-glucosidase activity